CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma
CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma
复制标题
DOI：
10.1007/s00432-010-0930-8
复制
发表时间：
2011-04-01
影响因子：
3.6
通讯作者：
Kimura, Tadashi
中科院分区：
文献类型：
--
作者：
Miyake, Takahito;Ueda, Yutaka;Kimura, Tadashi
CRABP1 是视黄酸功能的调节剂。本研究的目的是探讨CRABP1在卵巢癌中的表达及其临床意义。通过免疫组化分析100例不同组织学亚型的卵巢癌（包括浆液性和透明细胞腺癌）中CRABP1蛋白的表达。分析了 CRABP1 表达与临床特征（包括预后）的关系。 CRABP1 蛋白表达降低在浆液性和透明细胞腺癌亚型中尤其常见，分别占 50%（40 例中的 20 例）和 38%（26 例中的 10 例）。我们发现，无论疾病阶段如何，与保持表达的类似病例相比，在浆液性和透明细胞腺癌中，CRABP1 表达减少的病例的总体生存率显着较差（P 分别为 0.0073 和 0.049）。与 CRABP1 表达维持的病例相比，CRABP1 表达降低的浆液性和透明细胞腺癌病例的无病生存率显着较差 (P = 0.024)。多变量分析显示，CRABP1 表达降低是一个非常重要的预后因素（调整后风险比：8.189（95% CI，2.186-30.672，P = 0.0019））。本研究首次证明 CRABP1 表达降低有可能作为浆液性腺癌（最常见的组织学卵巢肿瘤类型）和透明细胞的预后标志物。经常表现出化疗耐药性的癌症。需要进一步的研究来阐明 CRABP1 蛋白表达如何改变以及 CRABP1 如何影响卵巢癌细胞。
CRABP1 is a modulator of retinoic acid function. The aim of the present study was to investigate CRABP1 expression and its clinical significance in ovarian carcinoma.Expression of CRABP1 protein was investigated by immunohistochemical analysis in 100 ovarian carcinomas of various histological sub-types, including serous and clear cell adenocarcinomas. Relationship of CRABP1 expression to clinical features, including prognosis, was analyzed.Reduced expression of CRABP1 protein was detected especially frequently in the serous and clear cell adenocarcinomas sub-types, 50% (20 of 40) and 38% (10 of 26) of cases, respectively. We found that in both serous and clear cell adenocarcinomas overall survival was significantly poorer in the cases with reduced CRABP1 expression compared to similar cases where expression was maintained, irrespective of the disease stage (P = 0.0073 and 0.049, respectively). Disease-free survival of the serous and clear cell adenocarcinoma cases with reduced CRABP1 expression was significantly poorer, compared to the cases whose CRABP1 expression was maintained (P = 0.024). Multivariate analysis showed that reduced expression of CRABP1 was a significantly important prognostic factor (adjusted hazard ratio: 8.189 (95% CI, 2.186-30.672, P = 0.0019)).The present study is the first to demonstrate that the reduced expression of CRABP1 has a potential as a prognostic marker for serous adenocarcinoma which is the most frequent histological ovarian tumor type and also for clear cell carcinoma that often exhibits chemo-resistance. Further study is necessary to clarify how CRABP1 protein expression was altered and how CRABP1 affects ovarian carcinoma cells.